/content/dam/genesiscare/headshots/uk-doctor-headshots/UK_Oncology_Head_Shot_GA_Miranda_Payne.jpg

Dr Miranda Payne

Dr Miranda Payne
Miranda
Payne
BM BCh FRCP DPhil Consultant Medical Oncologist

Expert in

Melanoma including mucosal melanoma and skin cancer

Overview

Centers

Oxford
Oxford
51.7239071200697, -1.2145938932540707
/uk/our-centres/oxford

Dr Miranda Payne is a Consultant in Medical Oncology, specialising exclusively in the treatment of skin cancers, with particular expertise in the systemic treatment of melanoma.

Miranda took a first in Physiology from the University of Oxford before completing her clinical training in 1999. In 2006 Miranda was awarded a Cancer Research UK Clinical Fellowship, spending four years researching DNA repair mechanisms at the Weatherall Institute of Molecular Medicine, leading to a DPhil in Medical Oncology, awarded by the University of Oxford. Specialist training was also completed in Oxford, where Miranda is the current Clinical Lead for the Oncology Department at the Oxford University Hospitals NHS Foundation Trust.  

In her NHS practise, recruitment to international, academic, industry-sponsored and observational clinical trials is a routine aspect of Miranda’s clinical practice, reflected in her publication record. She has a particular interest in the consequences of immunotherapy and in the management of mucosal melanoma.

Miranda is the Thames Valley and South Midlands Skin Cancer Research Lead, was an elected member of the National Cancer Research Institute Skin Group, is a co-author of the recently published national UK guidelines for the management of both Ano-uro-genital Mucosal Melanoma and Head & Neck Mucosal Melanoma, works with Melanoma Focus (the UK national charity dedicated to research, treatment, education and information for patients, their families and their clinical teams) leading on their recently published Patient Guide, and has been an editor of the Oxford Handbook of Oncology for almost 20 years. 

Expertise and interests

Expertise
  • Immunotherapy and targeted therapy for melanoma
  • Systemic treatment of mucosal melanoma
  • Systemic treatment of non-melanoma skin cancers (CSCC and BCC)
Interests
  • Adjuvant treatment of high risk melanoma
  • Systemic treatment of skin cancer
  • Management of mucosal melanoma

Publications and affliations

  • Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma Benjamin Fairfax, Chelsea Taylos, Robert Watson, Isar Nassiri, Zoe Traill, M Al-Mossaw, Julian Knight, Paul Klenerman, Miranda Payne, Mark R Middleton Nat Med 2020 Feb; 26(2): 193-199
  • Stereotactic radiosurgery combined with immune checkpoint inhibition for the treatment of melanoma brain metastases is associated with high levels of extracranial disease control and survivorship – an abscopal effect? Philip Webb, Mark Zorman, Rhona Watson, Gemma Austin, Carol Thurgood, Nick Coupe, Miranda Payne, Claire Hobbs, Neuro-oncology 23(Supplement_4):iv16-iv16
  • Association between a distinctive autoantibody-associated brainstem sensory syndrome and immune checkpoint inhibitors Valentina Damato, Antonio Berretta, Sudarshini Ramanathan, Sophia Michael, Nicholas Coupe, Miranda Payne, Sarosh Irani JAMA Neurol 2022; 79(9): 949-951
  • Implications of systemic adjuvant melanoma treatments for U.K. melanoma services: Results of the U.K. Melanoma Adjuvant Pathway Survey Oliver Cassell, Catherine Harwood, Melanie Hovey, Miranda Payne Eur J Cancer Care. 2022;e13565.
  • Oxford Handbook of Oncology, Oxford University Press, editors Jim Cassidy, Donald Bassett, Roy AJ Spence, Miranda Payne, Gareth Morris-Stiff

Professional memberships

  • Melanoma Focus professional membership
  • Association of Cancer Physicians
  • British Medical Association
  • Fellow of the Royal College of Physicians